Evidence map›Paper›PMID 34739463›Full record

ArticleActa bio-medica : Atenei Parmensis2021

Prevalence of SARS-CoV-2 infection in the workplace: results of a year of investigation in the Marche Nord companies.

Chiara Orlandi, Chiara Orlandi, Giuditta Fiorella Schiavano, Giorgio Brandi, Mauro Magnani, Anna Casabianca

Open access · greenAbstract read
In one paragraph

Article in Acta bio-medica : Atenei Parmensis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. SARS-CoV-2 RNA Detection on Environmental Surfaces in a University Setting of Central Italy.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Chiara OrlandiDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo". chiara.orlandi@uniurb.it.
Chiara Orlandia:1:{s:5:"en_US";s:70:"Department of Biomolecular Sciences, University of Urbino "Carlo Bo"";}. chiara.orlandi@uniurb.it.
Giuditta Fiorella SchiavanoDepartment of Humanities, University of Urbino "Carlo Bo". giuditta.schiavano@uniurb.it.
Giorgio BrandiDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo". giorgio.brandi@uniurb.it.
Mauro MagnaniDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo". mauro.magnani@uniurb.it.
Anna CasabiancaDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo". anna.casabianca@uniurb.it.
University of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe world of work has been profoundly affected by the COVID-19 pandemic since workplace activities involving close contact with coworkers and customers can lead to transmission of SARS-CoV-2 and compromise continuity of operations of workplaces. The Covid-Lab of University of Urbino and the Confindustria Pesaro Urbino association signed an agreement to support the Marche Nord companies in the adoption of anti-contagion safety protocols.

methodsAntibodies detection was performed using a rapid immunochromatographic test. Total RNA from nasopharyngeal swab was subjected to a real-time RT-PCR multiplex for the detection of RdRp specific gene and E gene of the SARS-CoV-2, and the internal control (human RNase P).

resultsBetween May 2020 and Apr 2021, over 10,000 rapid serological tests had been carried out on workers of 35 companies and in 5% of cases IgG or IgM were found (519). All the 519 swabs gave a valid result (RNAse P Ct≤40) with 105 positive results (20%) for SARS-CoV-2 with a Ct value ≤45. Overall, only 1% of samples resulted positive for viral RNA (105/10000).

conclusionsThe University of Urbino set up a rapid-response (within 24 h, generally <6 h) diagnostic centre for SARS-CoV-2 detection (Covid-Lab) allowing the companies to activate the optimal safety path to ensure the health and safety of workers in the workplace. Our observations during this first year of activity, highlight that in the workplace, the infection does not seem to spread if precautionary measures are followed and only 1% (1 worker out of 100) tested positive for the SARS-CoV-2 virus.

Indexed as

COVID-19SARS-CoV-2HumansPandemicsPrevalenceSerologic Tests

Identifiers

PMID34739463
PMCPMC8851024
OpenAlexW3209375123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.